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Abstract
Background: Progression of diabetic retinopathy occurs at least temporarily during pregnancy. Although the cause
of this progression is not entirely understood, the immune phenomenon and chronic inflammation may play a
significant role. During pregnancy in order to avoid fetus rejection, certain components of the immune system that
are knowingly implicated in the pathogenesis of diabetic retinopathy are activated including generalized leukocyte
activation and an increase in certain cytokine plasma levels. Activated leukocytes with up regulated adhesion
molecules have an increased potential to bind to the endothelium cells of blood vessels. Leukocyte-endothelial
interaction and the consequent leukostasis with capillary occlusion, ischemia and vascular leakage have a
substantial role in the development of diabetic retinopathy. Furthermore, certain increased cytokines are known to
cause blood-retinal-barrier breakdown whilst others promote angiogenic and fibrovascular proliferation and thereby
can also be implicated in the pathogenesis of this diabetic complication.
Presentation of the hypothesis: We hypothesized that the activation of the immune system during gestation
may have an influence on the course of retinopathy in pregnant diabetic women.
Testing the hypothesis: We suggest two prospective follow up studies conducted on women with type 1
diabetes mellitus. The first study would include a group of non-pregnant women and a group of diabetic women
undergoing normal pregnancy matched for age and duration of diabetes. In the second study pregnant women
would be divided into two groups: one with normal pregnancy and the other with preeclampsia. The procedure
and data collection in both studies will be identical: a complete ophthalmological examination, glycaemic control,
blood pressure measurement and venous blood samples for the determination of plasma levels of cytokines
(TNF-alpha, IL-1beta, IL-6, IL-8) and adhesion molecules (ICAM-1, VCAM-1).
Implications of the hypothesis: Considering the present assumption, the gestational immune activation could be
suggested as a potential risk factor for the development and progression of retinopathy in diabetic women. A
better understanding of immunomodulatory effects of pregnancy on diabetic retinopathy pave the way for further
investigations of the mechanism of its pathogenesis and could be essential for novel approaches to the treatment
of this serious sight threatening complication of diabetes mellitus.
Background
Diabetic retinopathy is a common and progressive micro-
vascular complication of diabetes mellitus and the lead-
ing cause of new blindness in the working age population
in developed countries [1]. Numerous studies have for-
merly demonstrated a deterioration of retinopathy in
diabetic women during pregnancy [2-4]. Although many
researchers have succeeded to clarify the connection
between retinopathy development and gestation, the
exact mechanism responsible for this is still not entirely
clear [2-9]. The consensus is that this mechanism is mul-
tifactorial with important contributory factors including
hyperglycaemia [3,4,7,8], duration of diabetes before
conception [3,4], baseline status of retinopathy [3,4,8],
rapid control of blood glucose during pregnancy [3,8],
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coexisting hypertension [2], preeclampsia [9] and changes
in retinal blood flow [9].
It has previously been established that immune phe-
nomenon and inflammatory reactions are involved in the
pathogenesis and progression of diabetic retinopathy
[10-13]. During pregnancy the maternal circulating
immune system undergoes modifications in cell counts,
phenotypes as well as the function and ability to produce
soluble factors such as cytokines. Different components
of the immune system maintain a balance between the
activation and suppression of the innate and adaptive
immune system branches. This in turn allows the mater-
nal defense mechanism capabilities to remain intact and
simultaneously plays a central role in the maternal adap-
tation in pregnancy to avoid fetal allograft rejection [14].
Increased level of hormones (estrogen, progesterone and
prolactin) during pregnancy may also contribute to the
changes of the maternal immune system. Immune and
endocrine cells possess the ability to synthesize and
express receptors for cytokines and hormones and by
binding to these receptors they can modulate the activity
of immune and endocrine cells. Thus the relationship of
these two systems and their mutual interactions via cyto-
kines which act as mediators enable hormones to also
have an effect on the course of diabetic retinopathy during
pregnancy [15].
A recent study addressing the association of inflam-
matory markers and diabetic retinopathy in pregnancy
failed to find statistically significant increases in levels of
interleukin-6 (IL-6) and vascular adhesion molecule-1
(VCAM-1) in the plasma of diabetic women compared
to non-diabetic controls, although the IL-6 value tended
to be higher in diabetic as opposed to nondiabetic
women [5]. However, this investigation did not draw a
comparison between obtained values and the values of
these same parameters in non-pregnant diabetic women.
In our opinion this problem should be considered from
another point of view. To clarify this issue it is essential
that the level of certain cytokines and adhesion mole-
cules as well as IL-6 and VCAM-1 is raised in pregnant
compared to non-pregnant women as a result of adapta-
tion of the immune system during pregnancy. In pre-
vious studies it has already been confirmed and proven
that all pregnant women demonstrate increased levels of
IL-6, IL-8, adhesion molecules and activation of leuko-
cytes in relation to the condition prior to pregnancy
[14,16-19]. We therefore presume that in healthy
women during gestation this increase does not cause
pathological changes whilst in pregnant diabetic patients
especially those with previous retinopathy and longer
duration of diabetes it may cause a progression of this
complication. In fact, increased levels of these molecules
which are found in all women, with and without dia-
betes, caused by pregnancy could therefore influence
retinopathy progression in diabetic women. However,
we maintain that the differences between pregnant and
non pregnant women are essential and not the differ-
ences between diabetic and non diabetic patients alone.
Hence, one could speculate that pregnancy itself may be
one of the causing factors for retinopathy progression
during gestation.
Thus, considering the existing knowledge and our own
presumption, it is reasonable to assume that the adapta-
tion of the immune system during gestation may also
contribute and be one of the causing factors for retino-
pathy progression in pregnant diabetic women.
Presentation of the hypothesis - how the maternal
immune system could influence the progression of
diabetic retinopathy during pregnancy
Several studies have been conducted in order to explain
the mechanisms underlying the progression of diabetic
retinopathy during pregnancy [2-9]. After adjusting to
the duration of diabetes, preexisting retinopathy prior to
conception, glycaemic and blood pressure control, cur-
rent pregnancy was found to be an important risk factor
in retinopathy progression. However, the exact mechan-
ism by which this progression occurs is not entirely
clear [2-9]. Capillary occlusion represents a characteris-
tic pathologic feature in early diabetic retinopathy and is
presumed to cause capillary non-perfusion, endothelial
cell damage and initiate a blood-retinal barrier break-
down as well as neovascularisation [20] [Figure 1]. The
exact mechanism by which capillary occlusion occurs is
still unclear but extending evidence suggests that it is
associated with increased leukocyte adhesion to the dia-
betic retinal vasculature. The increased leukocyte-
endothelial cell adhesion and consecutive leuokostasis is
a result of enhanced adhesion molecule expression such
as CD11a/CD18, intercellular adhesion molecule-1
(ICAM-1), VCAM-1, E-selectin and P-selectin on
endothelial cells and leukocytes as well as up regulation
of integrins which represent their counter-receptors
[21]. Recent reports have described normal pregnancy as
characterized by an activation of circulating leukocytes
as part of a generalized immune response. This leuko-
cyte activation is marked by up-regulation in the expres-
sion of different adhesion molecules such as CD11a,b/
CD18, CD54 (ICAM-1) and CD49d as well as integrins
and selectins present on the surface of circulating leuko-
cytes. Furthermore these activated leukocytes have the
increased potential to bind to the endothelium of blood
vessels via interactions with ICAM-1 and VCAM-1
molecules [16-18]. This demonstrates that one of the
essential pathologic events in the development of dia-
betic retinopathy is activated during pregnancy and
could therefore be at least partially responsible for its
progression in the gestation period.
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Several investigations have shown an increase in con-
centration of cytokines, growth factors and adhesion
molecules in patients with diabetic retinopathy which
may consequently stimulate endothelial cells and trigger
neovascularisation [Table 1]. In patients with prolifera-
tive diabetic retinopathy increased vitreous concentra-
tions of the interleukin-1beta (IL-1beta), IL-6, soluble
IL-2 receptor (sIL-2R) and IL-8 were found [12], whilst
the serum of same patients contained elevated levels of
tumor necrosis factor-alpha (TNF-alpha), IL-6, IL-8 and
sIL-2R [12,13,22]. Furthermore, it is also well known
that some cytokines are potent vascular permeability
factors. They may contribute to the early retinal micro-
vascular abnormalities induced by diabetes as well as
capillary leakage which is responsible for hard exudates
formation and macular edema development. Accumulat-
ing evidence suggests that different cytokines also play
major roles both in the establishment and in the main-
tenance of normal human pregnancy [18,19,23]. It is
documented that the serum value of IL-1beta, IL-6 [19]
and IL-8 [16] increase during the gestation period.
During pregnancy IL-6 in the serum of healthy women
progressively increased, reaching the highest levels in
the third trimester with a further increment at the onset
of labour [24]. It is well documented that IL-1beta up-
regulates adhesion molecules which are in turn vital
for the binding of leukocytes to the endothelial surface
[25], whilst IL-6 and IL-8 are among the most essential
cytokines implicated in the development of diabetic reti-
nopathy [12,13]. IL-6 and IL-8 are pro-inflammatory
cytokines that cause blood-retinal barrier breakdown by
opening tight junctions between retinal vascular
endothelial as well as the pigmented epithelial cells.
They therefore promote increased vascular permeability
and leakage and thus participate in the pathogenesis of
diabetic retinopathy [13]. IL-8 has an angiogenic and
fibrovascular proliferative effect on ocular tissue and is
implicated in processes of neovascularisation and
thereby in the development of proliferative diabetic reti-
nopathy [13,26]. The above mentioned activation of
these immunological mediators strongly suggests that
Enhanced adhesion molecule expression 
(CD11a/CD18, ICAM-1, VCAM-1, E-selectin and P-selectin, integrins) 
Increased leukocyte adhesion 
Leukostasis 
Capillary occlusion (non-perfusion) 
Ishaemia 
Blood-retinal barrier breakdown  Neovascularisation 
Figure 1 Pathogenesis of diabetic retinopathy. Abbreviations: ICAM, intercellular adhesion molecule; VCAM, vascular cell adhesion molecule.
Table 1 Cytokines, growth factors and adhesion
molecules involved in diabetic retinopathy*
Parameter DM without DR DM with NPDR DM with PDR
TNF-a No change Increased Increased
IL-1a Reduced Reduced Increased
IL-1b No change Increased No change
IL-4 No change Increased Reduced
IL-6 No change Increased Increased
IL-8 Increased Increased Increased
IL-10 Reduced No change Increased
VEGF Increased Increased Increased
EGF Increased Increased Increased
ICAM-1 Increased Increased Increased
VCAM-1 Increased Increased Increased
E-selectin Increased Increased Increased
* Changes relative to levels in non-diabetic control subjects.
Abbreviations: DM, diabetes mellitus; DR, diabetic retinopathy; NPDR,
nonproliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy;
TNF, tumor necrosis factor; IL, interleukin; VEGF, vascular endothelial growth
factor; EGF, epidermal growth factor; ICAM, intercellular adhesion molecule;
VCAM, vascular cell adhesion molecule.
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they take part in the development of diabetic retinopa-
thy during the gestation period.
Preeclampsia is a well recognized risk factor for the pro-
gression and deterioration of diabetic retinopathy during
pregnancy [9]. It is associated with increased systemic vas-
cular resistance, enhanced platelet aggregation, activation
of the coagulation system and endothelial cell dysfunction
as part of a general inflammatory reaction [27,28]. A nat-
ural inflammatory response whilst less prominent is also a
feature of healthy pregnancy in the third trimester [16,17].
In actual fact the results of several studies show that the
progression of retinopathy was particularly observed at
this time [4,8,29]. According to some investigations, a gen-
eralized inflammatory response in preeclampsia [27,28] is
significantly increased when compared to normal pregnant
and non-pregnant control subjects [30] [Table 2]. It is
noteworthy that both TNF-a and IL-6 are well recognized
as potential mediators of endothelial dysfunction in pree-
clampsia. IL-1b and IL-8 are able to induce endothelial
cell activation and upregulation of endothelial adhesion
molecules, which mediate the attachment of circulating
monocytes to the endothelium [27,28,31,32]. This observa-
tion supports and explains the concept that pre-eclampsia
is one of the risk factors for diabetic retinopathy develop-
ment during pregnancy.
It is commonly believed that the severity of diabetic
retinopathy may regress at least to some degree in the
postpartum period, although the rate and timing of this
regression is still unknown [2,29,33]. The diabetic
women should therefore be closely monitored until reti-
nopathy is stabilized [33]. It is assumed that the impact
and the immunological influence of pregnancy remains
till one year after delivery and that these postpartal
changes may be related to the course of some autoim-
mune diseases during this period [34].
It is a well-established fact that diabetes takes longer
than five years to develop visible morphological changes
corresponding to diabetic retinopathy [20,35]. Women
with gestational diabetes certainly would not develop
diabetic retinopathy during pregnancy and therefore
fundus examination in these women is not required
despite of their glucose blood level. In these women
hyperglycemia and all its possible consequences do not
have enough time to develop any complications result-
ing from diabetes [36]. Increased levels of certain factors
involved in the development of diabetic retinopathy
(such as cytokines and adhesion molecules as well as
leukocyte activation) during nine months of pregnancy
in healthy women do not cause alterations in the func-
tion and structure of blood vessels and therefore logi-
cally could not lead to microangiopathy. Therefore, in
healthy women changes accompanying the adaptation of
the immune system to pregnancy remain without conse-
quences. Alternatively, in women with diabetes changes
in the immune system and subsequent increased levels
of certain well-known risk factors throughout a period
of nine months may lead to a deterioration of retinopa-
thy. This is therefore consistent with established data
that the increased values of these risk factors are con-
nected to the progression of this complication in all dia-
betic patients [20,36]. Indeed, this is further supported
by clinical observations which prove that the duration of
disease and degree of retinopathy prior to conception
are established risk factors for its progression during
pregnancy [3,4,8].
Testing the hypothesis
Since our intention is to explore the impact of some
immunological changes during pregnancy on the devel-
opment of diabetic retinopathy we need to compare a
group of pregnant diabetic women and non-pregnant
diabetic women who are matched for age and duration
of the diabetes. With this knowledge we could therefore
establish whether adaptation of the immune system dur-
ing pregnancy in women with diabetes causes an
increase in the level of certain risk factors which could
additionally lead to an acceleration of retinopathy.
To verify our hypothesis we suggest two prospective
follow up studies conducted on women with type 1 dia-
betes mellitus. The first study should contain a group of
pregnant diabetic women undergoing normal pregnancy
and a group of non-pregnant diabetic women matched
for age and duration of diabetes. The second investiga-
tion should include pregnant diabetic women divided in
two groups: a group with normal pregnancy and a
group with complicated pregnancy namely preeclampsia.
The procedure and data collection in both investigations
will be identical.
Table 2 Cytokines and adhesion molecules in the third
trimester of normal pregnancy and pre-eclampsia*
Parameter Normal pregnancy Pre-eclampsia
TNF-a Increased Increased
IL-1a No change Increased
IL-1b Increased Increased
IL-4 No change/reduced No change/reduced
IL-6 Increased Increased
IL-8 Increased Increased
IL-10 No change/increased No change/increased
ICAM-1 Increased Increased
VCAM-1 Increased Increased
* Changes relative to levels in non-pregnant control subjects.
Abbreviations: DM, diabetes mellitus; DR, diabetic retinopathy; NPDR,
nonproliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy;
TNF, tumor necrosis factor; IL, interleukin; ICAM, intercellular adhesion
molecule; VCAM, vascular cell adhesion molecule.
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Pregnant diabetic women should be recruited as soon
as their pregnancy is diagnosed (usually between 5 and
10 weeks of gestation). They will be studied at the 12th -
14th week, 24th - 26th and 34th - 36th week of the gesta-
tion, and at 1 month, at 2 - 4 months, 6 - 7 months and
11 - 12 months postpartum. In the non-pregnant dia-
betic participants venous blood samples will be taken
and regular check ups will be conducted every 3 months
during an 18 month follow up period. Thus every visit
will comprise of a specified set of procedures. They will
include: a complete ophthalmological examination, gly-
caemic control, blood pressure measurement and
venous blood samples for the determination of plasma
levels of cytokines (TNF-a, IL-1b, IL-6, IL-8) and adhe-
sion molecules (ICAM-1, VCAM-1). The pregnant
women will also give urine samples in order to deter-
mine the presence and level of urine proteins.
A complete ophthalmological examination will include
measurement of visual acuity, intraocular pressure mea-
surement with Goldmann applanation tonometer, bio-
microscopy, indirect ophthalmoscopy and fundus
photography. Diabetic retinopathy will be graded from
fundus photographs which will be taken through dilated
pupils (by the use of tropicamide 5 mg/ml). The severity
of retinopathy will be assessed using two 50° color
slides, one centered at the macula and the other at the
optic nerve head disc and will be graded using a modifi-
cation of the Early Treatment Diabetic Retinopathy
Study (ETDRS) grading system [37].
The progression of retinopathy will be classified as
follows:
(1) No progression: no change or a decrease in DCCT
score during pregnancy, and
(2) Progression: an increase in the DCCT score by one
or more levels during pregnancy.
Glycaemic control will be assessed by measuring the
level of glycosylated haemoglobin (HbA1c). Blood pres-
sure will be regarded as increased when the following
two criteria are met at two measuring sessions of at
least 24 h apart: first, diastolic pressure is increased 15
mmHg or more from the first measurement during
pregnancy until the end of pregnancy and secondly,
when the final level has reached 90 mmHg or more.
Chronic hypertension and pregnancy-induced hyperten-
sion are defined as high blood pressure before 20 weeks
and after 20 weeks of gestation respectively.
Preeclampsia is defined as high blood pressure and
proteinuria (0.3 g or more/24 h) after 20 weeks of
gestation.
Implications of the hypothesis
In relation to previous data of known mechanisms of
diabetic retinopathy development [20-22,26] and the
established fact that some of the same immunological
changes occur during pregnancy [14,16-19,23,24], it is
therefore reasonable to hypothesis that activation of the
immune system during pregnancy could indeed partici-
pate in the aggravation of the course of retinopathy in
diabetic women.
It is possible that in diabetic women this could origi-
nate or accelerate biochemical and molecular mechan-
isms and pathways contributing to blood-retinal barrier
disruption, capillary occlusion and neovascularisation.
These assumptions also help explain how pregnancy
could participate in the development and progression of
retinopathy in diabetic women even in the presence of
good metabolic control and when retinopathy prior to
conception is minimal.
Knowledge of the actual pathogenetic mechanism of
diabetic retinopathy progression during pregnancy may
deem important to the fields of diabetology, endocrinol-
ogy and ophthalmology. Understanding the risk factors
contributing to the aggravation of diabetic retinopathy
during this period is helpful in designing criteria for the
team management of pregnant women with diabetes.
We should bear in mind that after pregnancy in a cer-
tain number of diabetic women pathological fundus
changes could regress at least in part [2,29]. Thus it would
be interesting to investigate and clarify the immunological
and other changes and conditions that occur during this
period with the aim of explaining the pathogenesis of this
regression. The understanding of the natural mechanisms
that initiate regression of retinopathy would be particularly
significant and more beneficial than understanding of the
pathogenesis of retinopathy formation alone. All this
acquired knowledge would be constructive and valuable in
the development and improvement of therapy related to
this complication of diabetes which in turn could then
imitate the natural physiological conditions and mechan-
isms that cause regression after birth.
The above mentioned observations pave the way for
further investigations of the mechanism of pathogenesis
of diabetic retinopathy development and even possible
regression. Moreover, knowledge of the molecules and
pathways involved may create new therapeutic options.
Needless to say, future research would clarify this issue.
A better understanding of immunomodulatory effects of
pregnancy on diabetic retinopathy would be essential for
novel approaches to the treatment of this serious sight
threatening complication of diabetes mellitus.
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